



Incyte to Report Fourth Quarter and Year-End 2022 Financial Results

January 17, 2023

WILMINGTON, Del.--(BUSINESS WIRE)--Jan. 17, 2023-- Incyte (Nasdaq:INCY) announced today that it has scheduled its fourth quarter and year-end 2022 financial results conference call and webcast for 8:00 a.m. ET on Tuesday, February 7, 2023.

The schedule for the press release and conference call/webcast is as follows:

- Q4 & YE 2022 Press Release: February 7, 2023 at 7:00 a.m. ET
- Q4 & YE 2022 Conference Call: February 7, 2023 at 8:00 a.m. ET
- Domestic Dial-In Number: 877-407-3042
- International Dial-In Number: 201-389-0864
- Conference ID Number: 13735569

If you are unable to participate, a replay of the conference call will be available for thirty days. The replay dial-in number for the U.S. is 877-660-6853 and the dial-in number for international callers is 201-612-7415. To access the replay you will need the conference ID number 13735569.

The live webcast with slides can be accessed at [Investor.Incyte.com](https://investor.incyte.com) and will be available for replay for 90 days.

About Incyte

Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit [incyte.com](https://www.incyte.com) and follow [@Incyte](https://twitter.com/Incyte).

View source version on [businesswire.com](https://www.businesswire.com/news/home/20230117005125/en/): <https://www.businesswire.com/news/home/20230117005125/en/>

Incyte Contacts

Media

Catalina Loveman
+1 302 498 6171
cloveman@incyte.com

Investors

Christine Chiou
+1 302 274 4773
cchiou@incyte.com

Source: Incyte